Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
September 18, 2023 09:05 ET | Atriva Therapeutics GmbH
Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the...
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study
May 28, 2020 03:00 ET | Atriva Therapeutics GmbH
ATR-002 mode of action inhibits SARS-CoV-2 viral propagation and prevents the cytokine storm as demonstrated in preclinical studiesAtriva’s lead product candidate is the only host-targeted antiviral...